Novo Nordisk AS Class B

NOVO B: XCSE (DNK)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|l@LOCK|<@LOCK|g#n>bzR

Novo Nordisk: Capital Markets Day Ambitions Look Similar to Our Projections; FVE Lowered Slightly

Novo hosted its 2026 Capital Markets Day on Sept. 21, where it disclosed 2030 financial targets, including mid-single-digit top-line growth and roughly steady operating margins. Shares fell 8%.

Sponsor Center